MDT

Medtronic plc (MDT) | Rumor.io

Medtronic

MDT

Attention (50-day avg)0.01%

Attention rank (50-day avg)#342

Bullish sentiment (50-day avg)94%

Price to earnings ratio21.8

Market capitalization114.5B

Earnings per share4.06

Dividend yield (TTM)3.22%

Revenue (annual)36.4B

Net income (annual)4.8B

Social

What share of all stock conversation is about MDT?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% +0	0% 0	0.02% +0.01	0.01% 0

Sep 1

Medtronic plc (MDT) announces a $700M strategic partnership with Cornerstone Robotics to expand global access to the Sentire Surgical System in select non-U.S. markets.
MDT beats Q1 adjusted EPS estimate of $1.39 with $1.45, and revenue estimate of $9.55B with $9.76B, also narrows FY27 EPS view to $5.94-$6.00 and raises organic revenue growth view to 7.25%-7.75%.
MDT raises FY27 organic revenue growth view to 7.25%-7.75% from 6.75%-7.25%, and announces a strategic investment of up to $80M in Pi-Cardia with an option to acquire the company for up to $210M.

Generated by AI

Sentiment

Of the messages about MDT that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100% 0	83.33% -9.19	91.81% -4.84	92.26% -0.6
Bearish	0% 0	16.67% +9.19	8.19% +4.84	7.74% +0.6

Bullish· Sep 1

Medtronic's Q1 earnings report exceeded expectations, with revenue rising 19.5% and adjusted EPS guidance raised to $5.94-$6.00.
The company's cardiovascular revenue grew 19.5% to $3.927B, driven by 29% Electrophysiology growth, and Medtronic lifted its FY27 non-GAAP EPS guidance.
Medtronic's stock price is expected to receive upward pressure due to the raised fiscal 2027 outlook, which may cause analysts and investors to increase forward revenue or earnings estimates.

Bearish· Jun 3

$MDT's share price decline YTD is prompting questions about which parts of the stock market are looking attractive to prospective investors.
Medtronic's poor performance has led to a 19% decline in its stock price on the quarter, with a recent green premarket pop not being a significant indicator of future movement.
The company's stock price is undervalued, with some analysts suggesting it could be worth at least $120 per share, but is currently trading at a lower level due to investor preference for tech stocks.

Generated by AI

Topics

Of the messages about MDT that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	0%	0%	5.26%	4.23%
Technical Analysis	0%	0%	0.42%	1.95%
Macro	50%	50%	2.28%	75.49%
Analysts	50%	50%	3.09%	5.1%
Earnings	0%	0%	88.94%	13.12%
Controversies	0%	0%	0%	0.12%

Earnings· Sep 1

Medtronic's Q1 earnings beat estimates, with revenue of $9.76B (+13.7% YoY) and adjusted EPS of $1.45 (+15.1% YoY).
The company raised its FY27 guidance, with adjusted EPS expected to be between $5.94-$6.00, and organic revenue growth guidance increased to 7.25-7.75%.
Cardiovascular revenue grew 19.5% YoY, with electrophysiology growth of 29%, and the company's CFO noted that strong operating performance and disciplined financial management drove the revenue and adjusted EPS beat.

Analysts· Apr 24

Medtronic ($MDT) is up over 3% after being upgraded by Wells Fargo, with a new target price of $100 from $77.
Analysts at Wells Fargo and Barclays expect Medtronic to benefit from a maturing product pipeline and improving medtech trends, with a favorable outcome from the FDA approval of the MiniMed 780G System.
Medtronic's stock is up after receiving two analyst upgrades, with Truist Financial raising its price target to $93 and a Wells Fargo analyst upgrading the stock to Overweight from Equal Weight.

Announcements· Feb 17

Medtronic ($MDT) announces first U.S. surgery with Hugo robotic-assisted surgery system performed at Cleveland Clinic.
Medtronic ($MDT) reports Q3 FY26 results: revenue $9.0 billion, +6.0% organic; GAAP EPS $0.89, non-GAAP EPS $1.36.
Medtronic ($MDT) reaffirms FY26 guidance for 5.5% organic growth, with strong performance in cardiovascular, cardiac ablation, and diabetes segments.

Controversies· May 20

Medtronic ($MDT) has settled a global patent litigation case with Edwards Lifesciences, agreeing to pay $750 million and quarterly royalties until April 2022.
The settlement is valued at over $1 billion, with Medtronic paying more than $1 billion to Edwards Lifesciences to settle the patent dispute.
The patent dispute was related to transcatheter heart valves, and the settlement has ended the ongoing patent feud between Medtronic and Edwards Lifesciences.

Technical Analysis· Jan 3

The author expects Medtronic plc ($MDT) to bounce from trend line support and potentially reach $0.09-$0.15 levels.
The 1-day chart shows a potential flip of $0.072, indicating a possible reversal in the stock's trend.
The author is analyzing the $MDT/USDT pair on a 1-day chart, looking for opportunities to buy the stock.

Generated by AI

Community

Of the messages about MDT, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	2.96%	14.14%	15.05%
Newcomers	100%	97.04%	85.86%	84.95%

Regulars· Sep 1

Medtronic's Q1 2027 earnings report highlights a 13.7% YoY revenue growth to $9.76B, with adj. EPS of $1.45, beating estimates.
The company raised its FY27 guidance, with adj. EPS forecast at $5.94-$6.00 and organic revenue growth projected at 7.25%-7.75%.
Medtronic also announced a $700M strategic partnership with Cornerstone Robotics to expand global access to its Sentire Surgical System in select non-U.S. markets.

Newcomers· Sep 1

Medtronic's Q1 earnings report exceeded expectations, with revenue of $9.76B and adj. EPS of $1.45, beating estimates of $9.54B and $1.39, respectively.
The company raised its FY27 organic rev growth outlook to 7.25-7.75%, and also raised its full-year non-GAAP EPS guidance to $5.94-$6.00.
Medtronic's cardiovascular revenue grew 19.5% to $3.927B, and its newer growth platforms, such as electrophysiology, drove strong demand.

Generated by AI

News

Medtronic (MDT) Registers a Bigger Fall Than the Market: Important Facts to Note

15h agoYahoo Finance

Medtronic PLC stock underperforms Tuesday when compared to competitors

15h agoMarketWatch

3 Absurdly Cheap Growth Stocks That Are Trading Below $100

Detailed price information for Nvidia Corp (NVDA-Q) from The Globe and Mail including charting and trades.

16h agoThe Globe and Mail

Gilead vs. Medtronic: Which Healthcare Stock Offers the Better Mix of Growth and Income?

2d agoYahoo Finance

Pfizer vs. Medtronic: Which Healthcare Turnaround is More Convincing?

Pfizer Inc. (NYSE:PFE) and Medtronic plc (NYSE:MDT) are both trying to prove that years of portfolio investment can translate into more durable growth, but the two healthcare giants are entering very different stages of their turnarounds. Pfizer is rebuilding around newer medicines as COVID revenue declines and generic and biosimilar competition approaches. Medtronic, meanwhile, is […]

2d agoYahoo Finance

Can Medtronic’s (MDT) Core Units Keep Up With Management’s New Bets?

Medtronic plc’s (NYSE:MDT) investment thesis rests on accelerating growth across its key innovation platforms. CEO Geoff Martha noted ongoing strength in core segments such as Cranial and Spinal Technologies, Surgical, and Cardiac Rhythm Management. This comes along with encouraging momentum in high-growth opportunities such as Hugo robotic surgery, Symplicity, Altaviva, Affera, and Stealth AXiS. Read […]

2d agoYahoo Finance

Also Discussed

Investors talking about MDT also mention

#	Name	Attention
1	Stryker CorporationSYK	0.01%+0.01
2	Insulet CorporationPODD	0%new
3	Boston Scientific Corp.BSX	0.03%-0.02
4	DexCom Inc.DXCM	0%0
5	Edwards Lifesciences CorporationEW	0%new
6	Abbott LaboratoriesABT	0%-0.03
7	Intuitive Surgical Inc.ISRG	0%0
8	Tandem Diabetes Care, Inc.TNDM	0%new
9	Johnson & JohnsonJNJ	0%-0.06
10	Zimmer Biomet Holdings, Inc.ZBH	0%0

Medtronic plc

Healthcare
Medical Devices

Medtronic plc is a global medical technology company that develops, manufactures, and sells device-based therapies and related services for a broad range of chronic and acute health conditions. Headquartered in Dublin, Ireland, and founded in 1949, Medtronic focuses on technologies used by hospitals, clinics, and physicians worldwide. The company operates through four main areas: its Cardiovascular Portfolio, offering products such as heart valves, stents, pacemakers, and defibrillators; its Neuroscience Portfolio, which provides spinal fixation systems, neurostimulation devices, and neurovascular products; its Medical Surgical Portfolio, supplying advanced surgical instruments, energy-based devices, and visualization tools; and its Diabetes Operating Unit, which delivers insulin pumps, continuous glucose monitoring systems, and related consumables. Medtronic plays a significant role in the healthcare sector by providing solutions that support the diagnosis, monitoring, and treatment of complex conditions, serving healthcare providers and patients across the United States, Europe, Japan, and other international markets.

Website

Location

Building Two

Galway, MN, H91 4K49

Ireland

Social

What share of all stock conversation is about MDT?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% +0	0% 0	0.02% +0.01	0.01% 0

Sep 1

Medtronic plc (MDT) announces a $700M strategic partnership with Cornerstone Robotics to expand global access to the Sentire Surgical System in select non-U.S. markets.
MDT beats Q1 adjusted EPS estimate of $1.39 with $1.45, and revenue estimate of $9.55B with $9.76B, also narrows FY27 EPS view to $5.94-$6.00 and raises organic revenue growth view to 7.25%-7.75%.
MDT raises FY27 organic revenue growth view to 7.25%-7.75% from 6.75%-7.25%, and announces a strategic investment of up to $80M in Pi-Cardia with an option to acquire the company for up to $210M.

Generated by AI

Sentiment

Of the messages about MDT that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100% 0	83.33% -9.19	91.81% -4.84	92.26% -0.6
Bearish	0% 0	16.67% +9.19	8.19% +4.84	7.74% +0.6

Bullish· Sep 1

Medtronic's Q1 earnings report exceeded expectations, with revenue rising 19.5% and adjusted EPS guidance raised to $5.94-$6.00.
The company's cardiovascular revenue grew 19.5% to $3.927B, driven by 29% Electrophysiology growth, and Medtronic lifted its FY27 non-GAAP EPS guidance.
Medtronic's stock price is expected to receive upward pressure due to the raised fiscal 2027 outlook, which may cause analysts and investors to increase forward revenue or earnings estimates.

Bearish· Jun 3

$MDT's share price decline YTD is prompting questions about which parts of the stock market are looking attractive to prospective investors.
Medtronic's poor performance has led to a 19% decline in its stock price on the quarter, with a recent green premarket pop not being a significant indicator of future movement.
The company's stock price is undervalued, with some analysts suggesting it could be worth at least $120 per share, but is currently trading at a lower level due to investor preference for tech stocks.

Generated by AI

Topics

Of the messages about MDT that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	0%	0%	5.26%	4.23%
Technical Analysis	0%	0%	0.42%	1.95%
Macro	50%	50%	2.28%	75.49%
Analysts	50%	50%	3.09%	5.1%
Earnings	0%	0%	88.94%	13.12%
Controversies	0%	0%	0%	0.12%

Earnings· Sep 1

Medtronic's Q1 earnings beat estimates, with revenue of $9.76B (+13.7% YoY) and adjusted EPS of $1.45 (+15.1% YoY).
The company raised its FY27 guidance, with adjusted EPS expected to be between $5.94-$6.00, and organic revenue growth guidance increased to 7.25-7.75%.
Cardiovascular revenue grew 19.5% YoY, with electrophysiology growth of 29%, and the company's CFO noted that strong operating performance and disciplined financial management drove the revenue and adjusted EPS beat.

Analysts· Apr 24

Medtronic ($MDT) is up over 3% after being upgraded by Wells Fargo, with a new target price of $100 from $77.
Analysts at Wells Fargo and Barclays expect Medtronic to benefit from a maturing product pipeline and improving medtech trends, with a favorable outcome from the FDA approval of the MiniMed 780G System.
Medtronic's stock is up after receiving two analyst upgrades, with Truist Financial raising its price target to $93 and a Wells Fargo analyst upgrading the stock to Overweight from Equal Weight.

Announcements· Feb 17

Medtronic ($MDT) announces first U.S. surgery with Hugo robotic-assisted surgery system performed at Cleveland Clinic.
Medtronic ($MDT) reports Q3 FY26 results: revenue $9.0 billion, +6.0% organic; GAAP EPS $0.89, non-GAAP EPS $1.36.
Medtronic ($MDT) reaffirms FY26 guidance for 5.5% organic growth, with strong performance in cardiovascular, cardiac ablation, and diabetes segments.

Controversies· May 20

Medtronic ($MDT) has settled a global patent litigation case with Edwards Lifesciences, agreeing to pay $750 million and quarterly royalties until April 2022.
The settlement is valued at over $1 billion, with Medtronic paying more than $1 billion to Edwards Lifesciences to settle the patent dispute.
The patent dispute was related to transcatheter heart valves, and the settlement has ended the ongoing patent feud between Medtronic and Edwards Lifesciences.

Technical Analysis· Jan 3

The author expects Medtronic plc ($MDT) to bounce from trend line support and potentially reach $0.09-$0.15 levels.
The 1-day chart shows a potential flip of $0.072, indicating a possible reversal in the stock's trend.
The author is analyzing the $MDT/USDT pair on a 1-day chart, looking for opportunities to buy the stock.

Generated by AI

Community

Of the messages about MDT, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	2.96%	14.14%	15.05%
Newcomers	100%	97.04%	85.86%	84.95%

Regulars· Sep 1

Medtronic's Q1 2027 earnings report highlights a 13.7% YoY revenue growth to $9.76B, with adj. EPS of $1.45, beating estimates.
The company raised its FY27 guidance, with adj. EPS forecast at $5.94-$6.00 and organic revenue growth projected at 7.25%-7.75%.
Medtronic also announced a $700M strategic partnership with Cornerstone Robotics to expand global access to its Sentire Surgical System in select non-U.S. markets.

Newcomers· Sep 1

Medtronic's Q1 earnings report exceeded expectations, with revenue of $9.76B and adj. EPS of $1.45, beating estimates of $9.54B and $1.39, respectively.
The company raised its FY27 organic rev growth outlook to 7.25-7.75%, and also raised its full-year non-GAAP EPS guidance to $5.94-$6.00.
Medtronic's cardiovascular revenue grew 19.5% to $3.927B, and its newer growth platforms, such as electrophysiology, drove strong demand.

Generated by AI

Medtronic

Social

Sep 1

Bullish· Sep 1

Bearish· Jun 3

Earnings· Sep 1

Analysts· Apr 24

Announcements· Feb 17

Controversies· May 20

Technical Analysis· Jan 3

Regulars· Sep 1

Newcomers· Sep 1

Medtronic (MDT) Registers a Bigger Fall Than the Market: Important Facts to Note

Medtronic PLC stock underperforms Tuesday when compared to competitors

3 Absurdly Cheap Growth Stocks That Are Trading Below $100

Gilead vs. Medtronic: Which Healthcare Stock Offers the Better Mix of Growth and Income?

Pfizer vs. Medtronic: Which Healthcare Turnaround is More Convincing?

Can Medtronic’s (MDT) Core Units Keep Up With Management’s New Bets?

Also Discussed

Medtronic plc

Company Information

Location

Medtronic (MDT) Registers a Bigger Fall Than the Market: Important Facts to Note

Medtronic PLC stock underperforms Tuesday when compared to competitors

3 Absurdly Cheap Growth Stocks That Are Trading Below $100

Gilead vs. Medtronic: Which Healthcare Stock Offers the Better Mix of Growth and Income?

Pfizer vs. Medtronic: Which Healthcare Turnaround is More Convincing?

Can Medtronic’s (MDT) Core Units Keep Up With Management’s New Bets?

Also Discussed

Social

Sep 1

Bullish· Sep 1

Bearish· Jun 3

Earnings· Sep 1

Analysts· Apr 24

Announcements· Feb 17

Controversies· May 20

Technical Analysis· Jan 3

Regulars· Sep 1

Newcomers· Sep 1